secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2021-11-05T23:59:59+00:00
Accession:  0001193125-21-321667
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia appoints Brendan Teehan as EVP, COO, Head of Commercial; two executives depart
--------------------------------------------------------------------------------

- Brendan Teehan promoted to EVP, Chief Operating Officer and Head of Commercial, effective immediately.
- Teehan previously SVP, Chief Insights and Analytics Officer; will lead all sales and marketing functions.
- Charmaine Lykins (SVP, Global Product Planning) and Amanda Morgan (SVP, Chief Revenue) leaving after transition period.
- Teehan has over 25 years healthcare experience, previously at Johnson & Johnson, Amgen, TESARO.
- Appointment comes as Acadia prepares for next phase of growth, per CEO Steve Davis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312521321667/0001193125-21-321667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312521321667/d257036d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-321667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer